The global radiopharmaceuticals market, valued at approximately USD 5.0 billion in 2023, is projected to grow to USD 16.6 billion by 2032, with an expected compound annual growth rate (CAGR) of 10.4% from 2024 to 2032. The increase is driven by a rising demand for diagnostic imaging and therapeutic applications, particularly in oncology and cardiology, due to the growing incidence of cancer and cardiovascular diseases globally. Technetium-99m is identified as the dominant radioisotope, while hospitals and clinics are the largest end-users. Regions such as North America show strong market presence due to advanced healthcare infrastructure, while the Asia Pacific region is anticipated to experience the fastest growth. Recent key developments include Bracco Japan's launch for diagnostic imaging products, Curium's acquisition of Monrol, and Lantheus's collaboration with the NIA for Alzheimer's research.
Fri, 04 Oct 2024 13:03:11 GMT | GlobeNewswire